Avapritinib mechanism of action?

How Does Avapritinib Work as a Cancer Treatment?

Avelumab's Avapritinib [1] is a cancer medication used to treat adults with advanced systemic mastocytosis (SM) harboring an Fc-receptor gamma chain (FCGR2A, FCGR3A, or FCGR3B) mutation. The treatment targets mast cells through a unique mechanism of action.

What Happens When Mast Cells Are Targeted?

Avapritinib specifically targets the extracellular KIT mutant receptor tyrosine kinase domain, which is present in mast cells. By binding to this region, Avapritinib blocks downstream signaling pathways, leading to the inhibition of mast cell growth and survival.

Blocking KIT Mutant Receptors

Mast cells in patients with SM often carry KIT mutations that lead to uncontrolled growth and disease progression. Avapritinib's mechanism involves the inhibition of these mutated KIT receptors, which are critical for mast cell activation and proliferation.

Blocking KIT Mutant Receptors

By inhibiting the mutated KIT receptors, Avapritinib reduces mast cell growth and activation, ultimately leading to decreased symptoms and disease progression in patients with SM.

Clinical Trials and Approval

Avapritinib was evaluated in a phase 1/2 study, demonstrating promising results in treating patients with SM. Based on these findings, the FDA granted accelerated approval for Avapritinib in May 2021. Additional phase 2 trials are ongoing to further evaluate its efficacy and safety.

Sources:
[1] DrugPatentWatch.com. (n.d.). Avapritinib. Retrieved from https://www.drugpatentwatch.com/avapritinib